These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23832427)

  • 1. Commentary.
    Mahler RJ
    Diabetes Metab Res Rev; 2013 Jul; 29(5):427-8. PubMed ID: 23832427
    [No Abstract]   [Full Text] [Related]  

  • 2. Saxagliptin, alogliptin, and cardiovascular outcomes.
    Scirica BM; Braunwald E; Bhatt DL
    N Engl J Med; 2014 Jan; 370(5):483-4. PubMed ID: 24476444
    [No Abstract]   [Full Text] [Related]  

  • 3. No heart risk--or benefit--from diabetes drug Onglyza.
    Harv Heart Lett; 2013 Dec; 24(4):8. PubMed ID: 27024811
    [No Abstract]   [Full Text] [Related]  

  • 4. Saxagliptin efficacy.
    Valiquette G
    Diabetes Obes Metab; 2010 Aug; 12(8):734; author reply 735. PubMed ID: 20590752
    [No Abstract]   [Full Text] [Related]  

  • 5. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
    Borja-Hart NL; Whalen KL
    Ann Pharmacother; 2010 Jun; 44(6):1046-53. PubMed ID: 20460554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations.
    Jialal I; Dhindsa S
    Metab Syndr Relat Disord; 2014 Apr; 12(3):157-8. PubMed ID: 24520851
    [No Abstract]   [Full Text] [Related]  

  • 7. ACP Journal Club. In at-risk patients with type 2 diabetes, saxagliptin and placebo did not differ for CV events.
    Morey-Vargas OL; Montori VM
    Ann Intern Med; 2014 Jan; 160(2):JC8-9. PubMed ID: 24445719
    [No Abstract]   [Full Text] [Related]  

  • 8. Saxagliptin, alogliptin, and cardiovascular outcomes.
    Standl E
    N Engl J Med; 2014 Jan; 370(5):483. PubMed ID: 24476445
    [No Abstract]   [Full Text] [Related]  

  • 9. In AF or VTE, warfarin dosing by genotype improved time in therapeutic range but not clinical outcomes.
    Dunn A
    Ann Intern Med; 2014 Mar; 160(6):JC9. PubMed ID: 24638187
    [No Abstract]   [Full Text] [Related]  

  • 10. Lessons from SAVOR and EXAMINE: some important answers, but many open questions.
    Schernthaner G; Sattar N
    J Diabetes Complications; 2014; 28(4):430-3. PubMed ID: 24713467
    [No Abstract]   [Full Text] [Related]  

  • 11. Saxagliptin and Heart Failure in the SAVOR-TIMI 53 Trial: Reflections on the Bradford Hill Criteria.
    Cebrián Cuenca AM; Orozco Beltrán D; Navarro Pérez J; Álvarez-Guisasola F; Núñez Villota J; Consuegra-Sánchez L
    Rev Esp Cardiol (Engl Ed); 2017 Dec; 70(12):1143-1144. PubMed ID: 28284632
    [No Abstract]   [Full Text] [Related]  

  • 12. Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial.
    Hardy G
    Cardiovasc J Afr; 2013 Aug; 24(7):290. PubMed ID: 24217308
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA approves saxagliptin for type 2 diabetes.
    Traynor K
    Am J Health Syst Pharm; 2009 Sep; 66(17):1513. PubMed ID: 19710429
    [No Abstract]   [Full Text] [Related]  

  • 14. Saxagliptin and tuberculosis.
    Prescrire Int; 2013 Jan; 22(134):17. PubMed ID: 23383408
    [No Abstract]   [Full Text] [Related]  

  • 15. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
    Schernthaner G; Cahn A; Raz I
    Diabetes Care; 2016 Aug; 39 Suppl 2():S210-8. PubMed ID: 27440835
    [No Abstract]   [Full Text] [Related]  

  • 16. [Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
    MMW Fortschr Med; 2014 Jul; 156(13):74-5. PubMed ID: 25318234
    [No Abstract]   [Full Text] [Related]  

  • 17. Diabetes: Cardiovascular safety of 'gliptin' therapy.
    Lim GB
    Nat Rev Cardiol; 2013 Nov; 10(11):616. PubMed ID: 24042219
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
    Greenhill C
    Nat Rev Endocrinol; 2013 Nov; 9(11):625. PubMed ID: 24061081
    [No Abstract]   [Full Text] [Related]  

  • 19. Place in therapy for liraglutide and saxagliptin for type 2 diabetes and FDA liraglutide warning.
    McFarland MS; Brock M; Ryals C
    South Med J; 2011 Aug; 104(8):612. PubMed ID: 21886074
    [No Abstract]   [Full Text] [Related]  

  • 20. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
    Simó R; Hernández C
    Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.